Comparative analysis of brivaracetam and levetiracetam in epilepsy treatment

Levetiracetam
DOI: 10.4103/etmj.etmj-d-24-00027 Publication Date: 2025-04-04T10:00:06Z
ABSTRACT
Abstract Epilepsy affects millions of people worldwide, necessitating effective and safe treatment options. Brivaracetam (BRV) levetiracetam (LEV) are antiepileptic drugs that target the synaptic vesicle protein 2A (SV2A). Despite similarities in their chemical structure, BRV LEV exhibit distinct pharmacological profiles. This study provides a detailed comparative analysis LEV, focusing on mechanisms action, preclinical profiles, pharmacokinetic pharmacodynamic properties. Clinical trial data highlight efficacy safety both drugs, with showing higher affinity for SV2A greater potency certain seizure models. Additionally, emerging strategies future directions epilepsy research discussed, highlighting potential advancing care.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (44)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....